Samadanifard Hossein, Barati Zahra, Ghanooni Amir Hossein, Eskandari Delaram, Ziaee Amir, Chehrehgosha Haleh, Sarv Fatemeh, Zahraei Shadi
Department of Endocrinology, Hazrat Rasoul Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Islamic Republic of Iran.
Master's Degree in Molecular Cell Microbiology.
Med J Islam Repub Iran. 2024 Sep 11;38:x. doi: 10.47176/mjiri.38.x. eCollection 2024.
Inflammation plays a significant role in the development and progression of type 2 diabetes (T2D). Empagliflozin, an SGLT2 inhibitor, has shown some anti-inflammatory effects in patients with T2D. This study aimed to evaluate the impact of empagliflozin on some inflammatory markers in T2D.
This retrospective single-arm cohort study included 40 patients with T2D who were treated with empagliflozin. Inflammatory markers such as serum level of erythrocyte sedimentation rate (ESR), high-sensitivity C-reactive protein (hs-CRP), neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and serum albumin were evaluated at baseline and 12 weeks after empagliflozin treatment. Statistical analysis used paired samples t test, and the statistically significant level was considered < 0.05.
After 12 weeks, a significant reduction was found in ESR (17.75 ± 15.7 mm/hr to 14.72 ± 10.93 mm/hr; = 0.025). However, the decrease in hs-CRP did not reach significance ( = 0.936). NLR did not show a significant reduction ( = 0.962), but there was a trend toward a significant decrease in PLR (107 ± 33 to 100 ± 35; = 0.053). The neutrophil count did not change significantly ( = 0.247), but the lymphocyte count significantly increased (2.43 ± 7.85 to 2.57 ± 7.45 109/l; = 0.014). Serum albumin showed a significant increase (42.8 ± 3.4 to 45.6 ± 3.2 g/l; < 0.001), indicating a decrease in inflammation.
Empagliflozin showed anti-inflammatory effects by reducing ESR and PLR and increasing serum albumin and lymphocyte count in adults with T2D. Monitoring inflammatory markers can serve as an indicator of treatment effectiveness in T2D patients.
炎症在2型糖尿病（T2D）的发生和发展中起重要作用。恩格列净是一种钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂，已在T2D患者中显示出一些抗炎作用。本研究旨在评估恩格列净对T2D患者某些炎症标志物的影响。
这项回顾性单臂队列研究纳入了40例接受恩格列净治疗的T2D患者。在基线时以及恩格列净治疗12周后，评估炎症标志物，如红细胞沉降率（ESR）、高敏C反应蛋白（hs-CRP）、中性粒细胞与淋巴细胞比值（NLR）、血小板与淋巴细胞比值（PLR）以及血清白蛋白水平。统计分析采用配对样本t检验，统计学显著性水平设定为<0.05。
12周后，ESR显著降低（从17.75±15.7毫米/小时降至14.72±10.93毫米/小时；P = 0.025）。然而，hs-CRP的降低未达到显著性（P = 0.936）。NLR未显示出显著降低（P = 0.962），但PLR有显著降低的趋势（从107±33降至100±35；P = 0.053）。中性粒细胞计数无显著变化（P = 0.247），但淋巴细胞计数显著增加（从2.43±7.85增至2.57±7.45×10⁹/升；P = 0.014）。血清白蛋白显著增加（从42.8±3.4克/升增至45.6±3.2克/升；P<0.001），表明炎症减轻。
恩格列净通过降低ESR和PLR以及增加T2D成年患者的血清白蛋白和淋巴细胞计数显示出抗炎作用。监测炎症标志物可作为T2D患者治疗效果的指标。
